Lonza overview sales 2006 rises 15.5%, totaling CHF 1415 mn

26 Jul '06

1 min read

Lonza continues to deliver: 17 percent increase in performance and decision taken to build out the Singapore Biopharmaceutical plant EBIT increased in the first half of 2006 by 17 percent to CHF 158 million. Lonza continues to successfully execute critical milestones in the long-term strategic plan.

Overview Sales in the first half of 2006 rose 15.5 percent, totaling CHF 1 415 million; almost half of this growth was due to the rise in raw material price.

Net income growth increased at a slower pace than EBIT in the first half of 2006 at 10.3 percent, due to higher one-time financing cost, and is expected to be on EBIT growth level by year end. Four hundred new colleagues joined the Lonza team in the first half year, to drive the implementation of our ambitious growth strategy.

Lonza, a chemical and biotechnology company driven by the life sciences, generated sales of CHF 2.52 billion in 2005.

Headquartered in Switzerland, Lonza operates 22 production and R&D sites around the world. Its 6300 employees are passionately committed to delivering sustainable value to their customers. Lonza is one of the leading custom manufacturers of chemical intermediates, active ingredients and biopharmaceuticals for the pharmaceutical and agrochemical industries.

Lonza Group

More Lonza News... More Textiles News - Switzerland...